LEXINGTON, Mass.--(BUSINESS WIRE)--March 30, 2006--NitroMed, Inc. (NASDAQ: NTMD) announced today that approximately 30 positions in research and development will be eliminated effective March 31, 2006 in a restructuring of the organization. The Company will focus on the continued development of both an extended release formulation of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride), as well as out-licensing and collaborations for its portfolio of nitric oxide-enhancing technologies, including NMI-3377, a late-stage pre-clinical cardio-renal compound.
